Free Trial

Immix Biopharma (NASDAQ:IMMX) Shares Up 1.5% - Here's What Happened

Immix Biopharma logo with Medical background

Shares of Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) traded up 1.5% on Tuesday . The stock traded as high as $2.71 and last traded at $2.66. 144,413 shares were traded during mid-day trading, a decline of 5% from the average session volume of 151,846 shares. The stock had previously closed at $2.62.

Analyst Ratings Changes

IMMX has been the topic of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Immix Biopharma in a research report on Wednesday, June 4th. Wall Street Zen upgraded shares of Immix Biopharma to a "hold" rating in a report on Friday, June 27th.

View Our Latest Research Report on IMMX

Immix Biopharma Stock Performance

The company's 50-day moving average price is $2.24 and its 200 day moving average price is $1.99. The stock has a market cap of $75.55 million, a PE ratio of -3.87 and a beta of 0.24.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Immix Biopharma stock. Jane Street Group LLC bought a new position in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 17,523 shares of the company's stock, valued at approximately $39,000. Jane Street Group LLC owned approximately 0.06% of Immix Biopharma at the end of the most recent quarter. Institutional investors own 11.26% of the company's stock.

About Immix Biopharma

(Get Free Report)

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.

Featured Stories

Should You Invest $1,000 in Immix Biopharma Right Now?

Before you consider Immix Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.

While Immix Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines